Literature DB >> 11592976

Role of p42/p44 mitogen-activated-protein kinase and p21waf1/cip1 in the regulation of vascular smooth muscle cell proliferation by nitric oxide.

P M Bauer1, G M Buga, L J Ignarro.   

Abstract

The purpose of this study was to determine the involvement of the p42/p44 mitogen-activated protein kinase (MAPK) pathway and induction of p21(waf1/cip1) in the antiproliferative effects of nitric oxide (NO) on rat aortic smooth muscle cells (RASMC). NO, like alpha-difluoromethylornithine (DFMO), interferes with cell proliferation by inhibiting ornithine decarboxylase (ODC) and, therefore, polyamine synthesis. S-nitroso-N-acetylpenicillamine or (Z)-1-[N-(2-aminoethyl)-N-(2-aminoethyl)-amino]-diazen-1-ium-1,2-diolate inhibited RASMC growth at concentrations as low as 3 microM, and DFMO elicited effects at concentrations of 100 microM or greater. The cytostatic effect of NO and DFMO was prevented by the MAPK kinase 1/2 inhibitors PD 098,059 or U0126. This finding suggests that the p42/p44 MAPK pathway is involved in the inhibition of RASMC proliferation by NO. Western blot analysis revealed that treatment of RASMC with NO or DFMO leads to activation of p42/p44 MAPK and induction of p21(waf1/cip1). This effect was prevented by MAPK kinase 1/2 inhibitors, suggesting that induction of p21(waf1/cip1) depended on activation of p42/p44. Moreover, activation of p42/p44 and induction of p21(waf1/cip1) were prevented by exogenous putrescine but not ornithine, suggesting this effect was due to the inhibition of ODC by NO or DFMO. Finally, activation of p42/p44 MAPK and induction of p21(waf1/cip1) were cGMP-independent. Neither 1H-(1,2,4)oxadiazolo[4,3-alpha]quinoxalin-1-one nor zaprinast influenced the cytostatic effect of NO or DFMO or their ability to activate these signal transduction pathways. These observations suggest that inhibition of ODC and accompanying putrescine production are the underlying mechanisms by which NO and DFMO activate the MAPK pathway to promote induction of p21(waf1/cip1) and consequent inhibition of cell proliferation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11592976      PMCID: PMC60134          DOI: 10.1073/pnas.211443198

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  34 in total

1.  Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide: evidence for the involvement of S-nitrosothiols as active intermediates.

Authors:  L J Ignarro; H Lippton; J C Edwards; W H Baricos; A L Hyman; P J Kadowitz; C A Gruetter
Journal:  J Pharmacol Exp Ther       Date:  1981-09       Impact factor: 4.030

2.  Tumor suppressor p53 but not cGMP mediates NO-induced expression of p21(Waf1/Cip1/Sdi1) in vascular smooth muscle cells.

Authors:  A Ishida; T Sasaguri; Y Miwa; C Kosaka; Y Taba; T Abumiya
Journal:  Mol Pharmacol       Date:  1999-11       Impact factor: 4.436

Review 3.  Polyamines.

Authors:  C W Tabor; H Tabor
Journal:  Annu Rev Biochem       Date:  1984       Impact factor: 23.643

4.  Polyamines in mammalian biology and medicine.

Authors:  H G Williams-Ashman; Z N Canellakis
Journal:  Perspect Biol Med       Date:  1979       Impact factor: 1.416

5.  Role of the arginine-nitric oxide pathway in the regulation of vascular smooth muscle cell proliferation.

Authors:  L J Ignarro; G M Buga; L H Wei; P M Bauer; G Wu; P del Soldato
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-20       Impact factor: 11.205

6.  IL-4 and IL-13 upregulate arginase I expression by cAMP and JAK/STAT6 pathways in vascular smooth muscle cells.

Authors:  L H Wei; A T Jacobs; S M Morris; L J Ignarro
Journal:  Am J Physiol Cell Physiol       Date:  2000-07       Impact factor: 4.249

7.  Inducible nitric oxide synthase (iNOS) expression upregulates p21 and inhibits vascular smooth muscle cell proliferation through p42/44 mitogen-activated protein kinase activation and independent of p53 and cyclic guanosine monophosphate.

Authors:  M R Kibbe; J Li; S Nie; S C Watkins; A Lizonova; I Kovesdi; R L Simmons; T R Billiar; E Tzeng
Journal:  J Vasc Surg       Date:  2000-06       Impact factor: 4.268

8.  Nitric oxide inhibits ornithine decarboxylase by S-nitrosylation.

Authors:  P M Bauer; J M Fukuto; G M Buga; A E Pegg; L J Ignarro
Journal:  Biochem Biophys Res Commun       Date:  1999-08-27       Impact factor: 3.575

9.  Arginase activity in human breast cancer cell lines: N(omega)-hydroxy-L-arginine selectively inhibits cell proliferation and induces apoptosis in MDA-MB-468 cells.

Authors:  R Singh; S Pervin; A Karimi; S Cederbaum; G Chaudhuri
Journal:  Cancer Res       Date:  2000-06-15       Impact factor: 12.701

Review 10.  Polyamine metabolism and function.

Authors:  A E Pegg; P P McCann
Journal:  Am J Physiol       Date:  1982-11
View more
  10 in total

1.  Fundamental role of nitric oxide in neuritogenesis of PC12h cells.

Authors:  Matsumi Yamazaki; Kenzo Chiba; Tetsuro Mohri
Journal:  Br J Pharmacol       Date:  2005-11       Impact factor: 8.739

2.  Nitric oxide and cisplatin resistance: NO easy answers.

Authors:  John J Turchi
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-13       Impact factor: 11.205

3.  The scaffolding protein EBP50 promotes vascular smooth muscle cell proliferation and neointima formation by regulating Skp2 and p21(cip1).

Authors:  Gyun Jee Song; Stacey Barrick; Kristen L Leslie; Philip M Bauer; Veronica Alonso; Peter A Friedman; Nathalie M Fiaschi-Taesch; Alessandro Bisello
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-10-27       Impact factor: 8.311

4.  Nitric oxide suppression of cellular proliferation depends on cationic amino acid transporter activity in cytokine-stimulated pulmonary endothelial cells.

Authors:  Louis G Chicoine; Louis G Chicione; Michael R Stenger; Hongmei Cui; Andrea Calvert; Rebecca J Evans; B Keith English; Yusen Liu; Leif D Nelin
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-01-14       Impact factor: 5.464

5.  Nitrite-generated NO circumvents dysregulated arginine/NOS signaling to protect against intimal hyperplasia in Sprague-Dawley rats.

Authors:  Matthew J Alef; Raghuveer Vallabhaneni; Evie Carchman; Sidney M Morris; Sruti Shiva; Yinna Wang; Eric E Kelley; Margaret M Tarpey; Mark T Gladwin; Edith Tzeng; Brian S Zuckerbraun
Journal:  J Clin Invest       Date:  2011-03-23       Impact factor: 14.808

6.  Single-nucleotide promoter polymorphism alters transcription of neuronal nitric oxide synthase exon 1c in infantile hypertrophic pyloric stenosis.

Authors:  Dieter Saur; Jean-Marie Vanderwinden; Barbara Seidler; Roland M Schmid; Marc-Henri De Laet; Hans-Dieter Allescher
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-02       Impact factor: 11.205

7.  Natriuretic peptide receptor-3 underpins the disparate regulation of endothelial and vascular smooth muscle cell proliferation by C-type natriuretic peptide.

Authors:  Rayomand S Khambata; Catherine M Panayiotou; Adrian J Hobbs
Journal:  Br J Pharmacol       Date:  2011-09       Impact factor: 8.739

8.  Complement C3 deficiency attenuates chronic hypoxia-induced pulmonary hypertension in mice.

Authors:  Eileen M Bauer; Han Zheng; Suzy Comhair; Serpil Erzurum; Timothy R Billiar; Philip M Bauer
Journal:  PLoS One       Date:  2011-12-14       Impact factor: 3.240

9.  cGMP-independent nitric oxide signaling and regulation of the cell cycle.

Authors:  Xiaolin Cui; Jianhua Zhang; Penglin Ma; Daniela E Myers; Ilana G Goldberg; Kelly J Sittler; Jennifer J Barb; Peter J Munson; Ana del Pilar Cintron; J Philip McCoy; Shuibang Wang; Robert L Danner
Journal:  BMC Genomics       Date:  2005-11-03       Impact factor: 3.969

10.  Coronary Serum Exosomes Derived from Patients with Myocardial Ischemia Regulate Angiogenesis through the miR-939-mediated Nitric Oxide Signaling Pathway.

Authors:  Hao Li; Yiteng Liao; Lei Gao; Tao Zhuang; Zheyong Huang; Hongming Zhu; Junbo Ge
Journal:  Theranostics       Date:  2018-03-07       Impact factor: 11.556

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.